^
Association details:
Evidence:
Evidence Level:
Sensitive: C4 – Case Studies
Title:

Metastatic Pancreatic Cancer with BRAF and P53 Mutations: Case Report of Therapeutic Response to Doublet Targeted Therapy

Published date:
10/13/2020
Excerpt:
She was found to have both a BRAF and P53 mutation, and received dabrafenib and trametinib with deep responses, both radiographically and biochemically (CA19-9)...To the best of our knowledge, this is the first case report showing a dramatic therapeutic response to combination therapy with dabrafenib and trametinib in metastatic pancreatic cancer.
DOI:
10.1159/000510096